2025
The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E
Ali M, Stockdale L, Sagara I, Zongo I, Yerbanga R, Mahamar A, Nikièma F, Tapily A, Sompougdou F, Diarra M, Bellamy D, Provstgaard-Morys S, Zoungrana C, Issiaka D, Haro A, Sanogo K, Sienou A, Kaya M, Traore S, Dicko O, Kone Y, Yalcouye H, Thera I, Diarra K, Snell P, Ofori-Anyinam O, Ockenhouse C, Lee C, Ewer K, Tinto H, Djimde A, Ouedraogo J, Dicko A, Chandramohan D, Greenwood B. The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E. Npj Vaccines 2025, 10: 26. PMID: 39915506, PMCID: PMC11802723, DOI: 10.1038/s41541-025-01078-0.Peer-Reviewed Original ResearchDoses of RTS,S/AS01RTS,S/AS01Dose of vaccineBooster dose of vaccineBooster doseAntibody responseCircumsporozoite proteinMalaria-endemic areas of AfricaRTS,S/AS01E malaria vaccineAntibody titresAnti-CSP antibody responsesBurden of malariaMalaria transmission seasonMalaria-endemic areasAnti-CSP antibodiesPlasmodium falciparum sporozoitesRisk of malariaMalaria vaccine RTS,S/AS01Incidence of malariaAssociated with protectionMultiplex assayYears of ageSevere malariaMalaria vaccineS/AS01
2020
In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso
Lingani M, Bonkian L, Yerbanga I, Kazienga A, Valéa I, Sorgho H, Ouédraogo J, Mens P, Schallig H, Ravinetto R, d’Alessandro U, Tinto H. In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal 2020, 19: 8. PMID: 31906948, PMCID: PMC6945612, DOI: 10.1186/s12936-019-3089-z.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsArtesunateBurkina FasoChildChild, PreschoolDrug CombinationsDrug Therapy, CombinationFemaleHumansInfantInhibitory Concentration 50LumefantrineMalaria, FalciparumMaleMass Drug AdministrationPlasmodium falciparumTreatment FailureTreatment OutcomeConceptsFirst-line treatmentArtemether-lumefantrineUncomplicated malariaFalciparum malariaTreatment failureOverall adverse event incidenceUncomplicated Plasmodium falciparum malariaEx vivo efficacyUnadjusted cure rateAdverse event incidenceUncomplicated falciparum malariaPlasmodium falciparum malariaP. falciparum susceptibilityMalaria-endemic areasEx vivo susceptibilityMass drug administrationP. falciparum isolatesEx vivo analysisAL armASAQ armOpen labelPrimary endpointRecurrent parasitaemiaEvent incidenceTreatment arms
2013
Comparison of field-based xenodiagnosis and direct membrane feeding assays for evaluating host infectiousness to malaria vector Anopheles gambiae
Gouagna L, Yao F, Yameogo B, Dabiré R, Ouédraogo J. Comparison of field-based xenodiagnosis and direct membrane feeding assays for evaluating host infectiousness to malaria vector Anopheles gambiae. Acta Tropica 2013, 130: 131-139. PMID: 24262642, DOI: 10.1016/j.actatropica.2013.10.022.Peer-Reviewed Original ResearchConceptsMosquito bitesOocyst infectionDirect membrane feeding assaysInfectious mosquito bitesAnopheles mosquitoesMembrane feeding assaysMalaria-endemic areasLow gametocyte densitiesCross-sectional surveyGametocyte densityEndemic areasDay 7Classical microscopic examinationHost infectiousnessBlood smearsOocyst prevalenceXenodiagnosisHost skinMembrane feederInfectionInfectious individualsInfectiousnessMicroscopic examinationHuman subjectsChildren
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply